

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1167)

VOLUNTARY ANNOUNCEMENT THE REGISTRATIONAL PHASE III CLINICAL TRIAL OF SHP2 INHIBITOR JAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIB APPROVED BY THE CENTER FOR DRUG EVALUATION (CDE) OF THE NMPA

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, the Company received the approval of registrational Phase III clinical trial of the combination therapy between its in-house KRAS G12C inhibitor Glecirasib and novel SHP2 inhibitor JAB-3312 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. JAB-3312 is the first SHP2 inhibitor entered into Phase III registration clinical study globally in combination with KRAS G12C inhibitor.

This approved study in China is a randomized active controlled Phase III clinical trial design to evaluate the efficacy and safety of JAB-3312 in combination with Glecirasib for first-line non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line NSCLC, which is the combination therapy of PD-1 antibody and chemotherapy.

Jacobio initiated clinical trials of SHP2 inhibitors in 2018. Data presented by Jacobio in an oral presentation (Abstract No.: 6530) at the 2023 European Society for Medical Oncology Annual Meeting (ESMO 2023) showed that among 129 patients with NSCLC, 58 patients were first-line treatment patients (including 7 dose groups), ORR (objective response rate) was 65.5% (38/58), and the DCR (disease control rate) was 100%. Among them, in the dose group of 800 mg Glecirasib (once daily) and 2 mg JAB-3312 (once daily for 1 week on, then 1 week off), the ORR was 86.7% (13/15). This clinical study is continuing to enroll patients.

The KRAS G12C inhibitors currently on the market have not been approved as first-line NSCLC treatments for KRAS G12C mutations. Jacobio’s JAB-3312 and Glecirasib are both oral formulations, and the combination therapy is also the first approved Phase III registration clinical trials or dual oral inhibitors in the first-line treatment of NSCLC worldwide.

About JAB-3312

JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with Glecirasib and other agents in China, the United States and Europe. The Phase III clinical trial of JAB-3312 in combination with KRAS G12C inhibitor Glecirasib has been approved by the CDE in February 2024.

About Glecirasib

Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. A number of Phase I/II clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. This includes a pivotal clinical trial in NSCLC in China; a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with Cetuximab in colorectal cancer, and a registrational pivotal clinical trial in pancreatic cancer.

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Glecirasib (JAB-21822) and JAB-3312 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, February 18, 2024

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.